← Back to headlines
Novo Nordisk's New Weight Loss Drug Underperforms Rival in Trial
Novo Nordisk's new weight loss injection has not performed as well as a rival drug from Eli Lilly in a recent clinical trial, causing a drop in its stock.
23 Feb, 14:29 — 23 Feb, 14:29
ℹOnly 1 source covers this story
